Gossamer Bio, Inc. (NASDAQ:GOSS – Get Free Report) has earned an average recommendation of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $246.40.
A number of equities research analysts have weighed in on GOSS shares. Leerink Partners raised Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $80.00 price objective on the stock in a report on Tuesday, July 28th. Wall Street Zen downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research note on Sunday, September 20th. Wedbush cut their target price on Gossamer Bio to $32.00 and set a “neutral” rating for the company in a research note on Wednesday, November 11th. Weiss Ratings cut Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, November 4th. Finally, Chardan Capital restated a “buy” rating on shares of Gossamer Bio in a research note on Monday, October 26th.
Read Our Latest Research Report on GOSS
Gossamer Bio Price Performance
GOSS stock opened at $10.97 on Monday. The company has a fifty day moving average price of $10.56 and a 200 day moving average price of $32.93. Gossamer Bio has a 12 month low of $8.29 and a 12 month high of $309.60. The company has a market cap of $67.14 million, a price-to-earnings ratio of -0.24 and a beta of 2.28.
Gossamer Bio (NASDAQ:GOSS – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($7.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.79) by ($3.57). The company had revenue of $38.43 million for the quarter, compared to analysts’ expectations of $12.16 million. As a group, analysts anticipate that Gossamer Bio will post -27.13 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Corient Private Wealth LP increased its holdings in Gossamer Bio by 41.3% in the second quarter. Corient Private Wealth LP now owns 5,632,698 shares of the company’s stock valued at $927,000 after buying an additional 1,647,315 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Gossamer Bio by 1,289.4% in the second quarter. Hsbc Holdings PLC now owns 1,583,118 shares of the company’s stock valued at $267,000 after purchasing an additional 1,469,175 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Gossamer Bio during the 2nd quarter worth approximately $65,000. Hhlr Advisors LTD. purchased a new stake in Gossamer Bio in the 2nd quarter valued at approximately $819,000. Finally, ARCH Venture Management LLC purchased a new stake in Gossamer Bio in the 2nd quarter valued at approximately $1,326,004. 81.23% of the stock is currently owned by institutional investors and hedge funds.
Gossamer Bio Company Profile
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. The company develops medicines for serious diseases, with a focus on pulmonary vascular conditions. Its lead candidate is seralutinib, an inhaled investigational therapy being studied for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Seralutinib is not an approved medicine. Gossamer has partnered with Chiesi Group to advance its development.
Further Reading
- Five stocks we like better than Gossamer Bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
